Labcorp offers timely, accurate and convenient screening options that can help curb rising STI rates in the U.S.
Most recent data available from the Centers for Disease Control and Prevention showed that chlamydia and gonorrhea were on the rise for the sixth year.1 With many patients being unwilling to admit to being sexually active,2 many chlamydia and gonorrhea infections remain undiagnosed and untreated. As many as 10-20% of untreated chlamydia or gonorrhea infections progress to pelvic inflammatory disease (PID).3
An estimated one in five people in the U.S. has an STI.2 In 2019, there were 68 million new cases of STIs in the U.S.—up from 26 million in 2018—almost half of which were among youth aged between 15 and 24.2 Nearly $962 million in direct medical cost has been attributed to both chlamydia and gonorrhea.2
The newly released “Sexually Transmitted Infections Treatment Guidelines, 2021” from the Centers for Disease Control and Prevention advocates for a new approach to screening for C. trachomatis and N. gonorrhoeae by introducing the concept of opt-out testing.
Per the updated CDC guidelines, opt-out chlamydia and gonorrhea screening among young and adolescent females can increase screening, save on costs and ultimately identify more infections among patients who may not be comfortable disclosing sexual behavior.4